Moderna's mFlusiva is the first mRNA influenza vaccine cleared in the U.S. Here is who it is for, what the trial found, and how to discuss it with a clinician before flu season.
Moderna's mFlusiva became the first FDA-approved influenza vaccine built on mRNA technology on August 5, 2026. That makes it a genuine medical first—not simply another seasonal flu-shot brand.
The vaccine is authorized for adults 50 years and older. Its arrival matters because influenza remains disproportionately hard on older adults, and mRNA manufacturing can potentially make strain updates more nimble than conventional egg-based production.
In a roughly 40,805-person study, mFlusiva showed 26.6% greater relative vaccine efficacy against laboratory-confirmed influenza than a standard comparator vaccine in the studied population. That is an encouraging comparative result, but it does not mean every individual is 26.6% less likely to get sick, nor does it replace the need for annual vaccination.
For adults 65 and older, the approval pathway includes post-marketing research to further confirm clinical benefit. Ask a pharmacist or clinician which flu vaccine best fits your age, prior reactions, medical history, and local availability.
Rather than delivering a weakened or inactivated virus, an mRNA vaccine gives cells temporary instructions to make a selected influenza protein. The immune system then learns to recognize it. The mRNA does not change a person's DNA and does not stay in the body permanently.
The practical benefit researchers are watching is speed: once experts select seasonal strains, mRNA platforms may help manufacturers update production more quickly. Real-world effectiveness will still depend on the match between circulating strains and the vaccine formulation.
mFlusiva may be a discussion point for adults 50+ who want to compare available flu shots before the 2026–27 season. People with a history of severe allergic reaction to a vaccine component, current moderate or severe illness, or complex immune conditions should get individualized advice.
Vaccination is not a replacement for seeking care for warning signs such as trouble breathing, persistent chest pain, confusion, dehydration, or symptoms that rapidly worsen.
A thermometer can help document a fever when you are ill, but it cannot diagnose influenza or determine whether you need antiviral treatment. We may earn a commission from the following link at no extra cost to you.
mFlusiva is a meaningful first: the first mRNA flu vaccine in the U.S. for adults 50+. The trial signal is promising, but the best choice remains individual. Compare it with the other recommended seasonal vaccines with a pharmacist or clinician, and do not delay care if respiratory symptoms become severe.